BioSpace News Archive

Kura Oncology, Inc. reported second quarter 2023 financial results and provided a corporate update.

Lexicon Pharmaceuticals, Inc., reported financial results for the three months ended June 30, 2023 and provided an update on key corporate milestones.

LianBio (Nasdaq: LIAN) today announced the first patient has been dosed in its Phase 1 clinical trial of BBP-398, an investigational SHP2 inhibitor, in combination with AstraZeneca’s osimertinib, an epidermal growth factor receptor (EGFR) inhibitor, for the treatment of patients with non-small cell lung cancer (NSCLC) with EGFR mutations.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced financial results for its second quarter ended June 30, 2023.

Sight Sciences, Inc., an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, reported financial results for the second quarter ended June 30, 2023 and reaffirmed guidance for full year 2023.

Cytokinetics, Incorporated reported financial results for the second quarter of 2023. Net loss for the second quarter was $128.6 million, or $1.34 per share, compared to net loss for the second quarter of 2022 of $19.8 million, or $0.23 per share.

NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a clinical-stage biotechnology company focused on discovering and developing transformative therapeutics for patients, today reported financial results for the quarterly period ended June 30, 2023 and provided business highlights.

Onconova Therapeutics, Inc. announced that the Company intends to release its second quarter 2023 financial results on Thursday, August 10, 2023.

ResMed Inc. announced results for its quarter ended June 30, 2023.

OPKO Health, Inc. reports business highlights and financial results for the three and six months ended June 30, 2023.